NPI: 1891980124 · SEMINOLE, OK 74868 · General Acute Care Hospital · NPI assigned 09/10/2007
Authorized official LALOR, PAULA controls 20+ related entities in our dataset. Read more
| Authorized Official | LALOR, PAULA (DIRECTOR/DELEGATED OFFICIAL) |
| NPI Enumeration Date | 09/10/2007 |
Other providers sharing the same authorized official: LALOR, PAULA
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 10,934 | $646K |
| 2019 | 9,405 | $651K |
| 2020 | 8,242 | $517K |
| 2021 | 16,340 | $1.02M |
| 2022 | 9,422 | $626K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 99283 | Emergency department visit for the evaluation and management, moderate severity | 8,983 | 8,838 | $1.38M |
| 99284 | Emergency department visit for the evaluation and management, high severity | 3,816 | 3,764 | $854K |
| 99285 | Emergency department visit for the evaluation and management, high severity with immediate threat to life | 1,201 | 1,176 | $286K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1,514 | 1,474 | $173K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 2,044 | 2,002 | $92K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1,253 | 1,219 | $77K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 696 | 691 | $62K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 2,859 | 2,793 | $59K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 2,013 | 1,987 | $56K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 371 | 365 | $51K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 863 | 858 | $43K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 2,883 | 2,866 | $41K |
| 80053 | Comprehensive metabolic panel | 4,019 | 3,895 | $38K |
| 96375 | Therapeutic injection; each additional sequential IV push | 844 | 809 | $33K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 228 | 133 | $33K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 3,898 | 3,767 | $27K |
| 71045 | Radiologic examination, chest; single view | 2,334 | 2,283 | $24K |
| 87428 | 377 | 377 | $21K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 221 | 220 | $15K |
| 87081 | 2,147 | 2,137 | $13K | |
| 36415 | Collection of venous blood by venipuncture | 5,363 | 5,128 | $12K |
| 87430 | 804 | 793 | $12K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 139 | 138 | $8K |
| 96361 | Intravenous infusion, hydration; each additional hour | 161 | 157 | $7K |
| 87420 | 448 | 445 | $5K | |
| 97597 | 286 | 144 | $5K | |
| 84443 | Thyroid stimulating hormone (TSH) | 340 | 340 | $5K |
| 70450 | Computed tomography, head or brain; without contrast material | 77 | 76 | $3K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 463 | 454 | $3K |
| 85027 | 350 | 349 | $2K | |
| 71046 | Radiologic examination, chest; 2 views | 123 | 120 | $2K |
| 83690 | 296 | 286 | $2K | |
| 84439 | 233 | 233 | $2K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 15 | 15 | $2K |
| 83036 | Hemoglobin; glycosylated (A1C) | 176 | 176 | $1K |
| 81001 | 512 | 505 | $1K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 20 | 20 | $1K |
| 81003 | 628 | 614 | $1K | |
| 81025 | 151 | 151 | $1K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 12 | 12 | $1K |
| 80061 | Lipid panel | 83 | 83 | $945.62 |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 15 | 15 | $769.65 |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 79 | 58 | $480.72 |
| 84484 | 25 | 25 | $321.98 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 12 | 12 | $315.96 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 12 | 12 | $312.10 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 12 | 12 | $304.10 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 20 | 20 | $235.40 |
| 83655 | 14 | 14 | $172.20 | |
| 87040 | 12 | 12 | $161.85 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 234 | 225 | $101.04 |
| 87086 | Culture, bacterial; quantitative colony count, urine | 14 | 14 | $96.52 |
| 82550 | 12 | 12 | $69.48 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | 26 | 25 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 119 | 118 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 25 | 25 | $0.00 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 451 | 441 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 17 | 15 | $0.00 |